Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vivione Biosciences (V.VBI) is on trend, accelerating product development

Stockhouse Editorial
0 Comments| August 16, 2013

{{labelSign}}  Favorites
{{errorMessage}}

Calgary biotech small cap, Vivione Biosciences Inc. (TSX:V.VBI, Stock Forum) is paddling hard just as a wave appears to be breaking around them, with the announcement that they’ll be partnering up with Kirkegaard & Perry Laboratories Inc. to get their RAPID-B food-borne pathogen detection platform to market.

Vivione (formerly PACE Partners Inc) executives have built their business around commercialization of RAPID-B, and the inclusion of KPL’s Bac-Trace affinity-purified primary antibodies in the system will bring the starting line way closer for the $16 million market cap outfit.

As the company explains it, the promise of RAPID-B is that it has the potential to provide food pathogen detection down to a single cell in as little as seven hours, as opposed to the 48 hours for competing methods.

At a time when billions of dollars are being spent recalling food products on a regular basis when bacterial outbreaks are found in the supply chain, and with the organic and pesticide-free sector experiences a massive growth spurt that makes testing all the more important, the time couldn’t be better for Vivione to emerge with a faster, more efficient, easier to use testing unit – one developed in collaboration with the United States Food & Drug Administration.

“Vivione collaborated with the U.S. Food and Drug Administration’s National Center for Toxicological Research (NCTR) over the past 6 years to accomplish the development and testing of the RAPID-B system,” said Kevin Kuykendall, Chief Executive Officer of Vivione in a press release Wednesday.

“The strategic relationship with KPL enables us to immediately expand our product offerings and get to market much faster by leveraging their leadership expertise in antibody-based reagent production.”

KPL is a veteran outfit with twenty years in the business of providing antibodies for Salmonella, STECs, E. coli, Listeria and Campylobacter, so partnering up brings a high quality consistent component to Vivione’s system.

The announcement of the new collaboration follows similar earlier announcements of a distribution deal with Quip Laboratories, and research collaborations with the University of Arkansas Department of Food Science and Agriculture Center for Food Safety.

The share price for V.VBI settled in at $0.20 at the time of writing, $0.02 up from the 52-week low. Nearly 60,000,000 shares are outstanding.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.